About us

We are a team of more than 40 biopharma commercial leaders, R&D managers, hands on, AI educated programmers, CRO & regulatory experts (former Parexel), specialty medicines experts including rare diseases (Roche, AstraZeneca, Biogen, Cubist, Sobi), finance operational and corporates (Harvard, Stanford, Oxford, Kellogg EMBAs), legal EU and OECD / IP specialists (Switzerland, EU27, USA, OECD, Swiss Patent Box) governed only in Switzerland (AG, GmbH’s) for the world. We hold more than 25 years of experience working together in the most successful, fulfilling parts of our careers where we bonded – mostly at industry segment leaders (Roche Dx, Roche Pharma, Biogen, AstraZeneca EMEA, globally, Parexel Boston, USA, for Clinical Trials in Oncology. Many hold late stage global leadership (boards) still today and we are focused on R&D, regulatory, launch services for and from many biotech companies. We manage IP and patents in all our companies and consider this optimisation over the entire life cycle as the “core” together with the Swiss Patent Box (SPB) regime since 2022. The “glue” and seamless cooperation, flow of solutions, team-work gives us the edge over others, every day. It also provides happiness, joy and high performance – some call it “flow”. We feel deep satisfaction because we help the “ethically right”, best things of innovation for people and animals come to markets. We only focus on breakthroughs, hard to put together and orchestrate, which this team has proven to do, again and again. We have financial oversight (eqswiss.com) and smartest AI development put in our best way in place (swissexel.com). We deliver breakthroughs, swiftly and smartly, IF they can be delivered in a smart way.

We come from different backgrounds, predominantly sciences, business and commercialisation, biotechnology and high-tech from medical technologies and IP. We focus on life saving medicines, IT and machine learning (AI), engineering improvements as drug delivery. We do a lot in immunology, inflammation and oncology. We learn from major failures in severe diseases, death and their challenges. Life shortening, from where we work back, to fix the junctions, the failures, the “could be done better, or be solved by smarter ways, ideally a breakthrough innovation – and patented / IP. Nature is complex, smart. Cells and organisms want to survive and prosper, even after the on switch of a malignant gene from earliest days, or caused by viruses or outside.

We added solid business, financial and leadership skills (Harvard, Kellogg Northwestern, Stanford, St. Gallen, Hagen, Oxford University), latest gen. and agentic AI and program and code everything ourselves (Oxford, MIT, Stanford). We protect cashflow wherever we can, reduce risks, add legal skills for IP and patents (Mannheim, St. Gallen, Hagen, Insead, New York) and reduce risks for investors – and ourselves as owners. It is an ethical mandate to protect capital and do the most from capital. We govern our portfolio in a lean and smart way (eqswiss.com) and provide all aspects of PE and cashflow driven finance and related supervision (Harvard, USA, Oxford, Kellogg Northwestern, St. Gallen) for value creation at lowest risks along the lifecycle of our investments, normally 4 to 5 years, or longer term..

We hate risk and reduce it wherever we can. We love volatility in innovation markets but we hate risks. We add more than minimal numbers of patients e.g. in Phase I or animal trials – if this is adding value. For a better data pictures, we take some time and put assets in – as it mostly pays out financially. We work in breakthroughs with better predictive guidance early, to then negotiate fast-track designations and approvals with leading authorities (FDA, USDA, Swissmedic, EMA). We can live with volatility in financial exit markets well, as we are “end-to-end financed” while risks, we try to reduce. We go fast but take the time where things are important. So when we want to go fast, we go slow where it is needed. As EDCs are “end-to-end” financed, we can work, focus and concentrate easily – for better results.

We operate and grow based on our NEMOO AI Value Builders EDC approach. It is a newly put together, EDC model (ethics driven) and leads all breakthrough technologies and solutions with precision, calmness and a lot of focus on execution forward. We manage with transparency, financial focus, “EDC’s capital first approach” and EDC leadership with suppliers, or we change, with supervision and coaching to get innovation into markets quickly. We also do early access programs, wherever possible. This is an ethical mandate, and why we hate “games” and “complexity” along the way – especially when the success is obvious. We want to see “new customers in global markets with our newly developed therapies and cures” from our EDC “end-to-end” investments. We protect the entrusted capital a lot (eqswiss.com), constantly. The capital took all the risk initially and we only go for 2-4 companies per year. We set it up, provide management, IP / patents excellence and filings, board support, give free advisory, and have investment cycles of 4-5 years or longer. We target EBITA, EV of 4-8 x or more, partly above 60 in breakthroughs in specific areas. We have seen IRRs of 18% up to 67% (risk adjusted) or 92% p.a. even in one case of a life saving therapy in Switzerland – USA and EU27 based on Swiss Patent Box, OECD 2022 regulations (adding another +34 to +38% of total EV upon initiation).

We roll over after 4-5 years, also for investors, but are flexible. We reduce risks and continue our “investors first” until final global launches (ROFRs, as a principle) and plan to go with industry leaders for global launches. We can do MBOs, pre-IPOs and IPOs, all limited to 33% debt to equity ratio for preparation of commercial or global partnerships. We like partnerships with global leaders, as this brings the benefits of life saving or life prolonging therapies fully and faster to global markets and patients. So, we are EDCs also during exits and global launches.